Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy

• Published in: Cancer immunology research Vol. 7; no. 10; p. 1570
• Main Authors: Goodman, Aaron M, Sokol, Ethan S, Frampton, Garrett M, Lippman, Scott M, Kurzrock, Razelle
• Format: Journal Article
• Language: English
• Published: United States 01.10.2019

Programmed death receptor-1/ligand 1 (PD-1/L1) antibodies can induce durable remissions in malignancies. However, response rates are only approximately 10% to 20% in unselected patients versus approximately 50% in microsatellite instability-high (MSI-high) tumors, probably related to high tumor muta...